Wikimedia
Scientists announced that the world’s first “tooth regrowth medicine” will begin clinical trials in September at Kyoto University Hospital.
Once the medicine’s safety is established, it will be tested on patients born without a full set of teeth to assess its effectiveness. The goal is to have the medicine available for sale by 2030.
About 1% of the population is affected by congenital tooth deficiency, with around 0.1% having oligodontia, a hereditary condition where six or more teeth are missing.
Kitano Hospital in Osaka’s Kita Ward, participating in the study, stated that the first phase of clinical trials will run from September this year until August 2025.
Wikimedia
In the next phase, Kitano Hospital will administer the medication to children aged 2 to 7 with congenital tooth deficiency, specifically those missing at least four teeth from birth.
The tooth regrowth medicine works by deactivating a protein called USAG-1, which prevents teeth from growing. Researchers hope that in the future, the medicine could help people with congenital conditions and those who have lost teeth due to cavities or injuries.
source Kitano Hospital
Leave A Comment